Soluble fas is a marker of coronary artery disease in patients with end-stage renal disease

American Journal of Kidney Diseases

Volumn 38, Issue 6, 2001, Pages 1271-1276

  Hébert, Marie Josée ^a   Masse, Mélanie ^a   Vigneault, Normand ^a   Sirois, Isabelle ^a   Troyanov, Stéphan ^a   Madore, François ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Apoptosis; Atherosclerosis; Coronary artery disease (CAD); End stage renal disease (ESRD); Hemodialysis (HD); Inflammation; Risk factors; Soluble fas (sFas); Soluble fas ligand (sFas L)

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FAS ANTIGEN; FAS LIGAND; INTERCELLULAR ADHESION MOLECULE 1;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; SMOKING;

EID: 0035720015     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.29224     Document Type: Article

References (26)

1. Atherosclerosis-An inflammatory disease
2. Accelerated atherosclerosis in prolonged maintenance hemodialysis
3. Cardiovascular complications in renal failure
4. Risk factors for cardiac morbidity and mortality in dialysis patients
5. Outcome and risk factors for ischemic heart disease in chronic uremia
6. C-reactive protein: A risk factor for coronary, cerebral and peripheral atherosclerosis in dialysis patients
7. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
8. Inflammation, aspirin, and risk of cardiovascular disease in apparently healthy men
9. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
10. Apoptosis in human atherosclerosis and restenosis
11. Is extravasation a Fas-regulated process?
12. Changing concepts of atherogenesis
13. Death receptors: Signaling and modulation
14. Clinical implications of circulating soluble Fas and Fas-ligand In patients with acute myocardial infarction
15. Soluble Fas/APO-1 splicing variants and apoptosis
16. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability
17. Fas is expressed in human atherosclerotic intinja and promotes apoptosis of cytokine-primed human vascular smooth muscle cells
18. The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions
19. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure
20. Fas-Fas ligand system in the peripheral blood of patients with renal diseases
21. Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: Soluble Fas isoform is an independent risk factor for prognosis
22. Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma